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The role of mandatory lifelong annual surveillance
after thoracic endovascular repair
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Thoracic endovascular aortic repair (TEVAR) has become an attractive and well-accepted option for the management of
the various thoracic aortic pathologies that vascular surgeons are confronted with. As in the abdominal aorta, current
management trends include the treatment of younger patients with longer life expectancies, raising the issue of
postoperative surveillance. There are several relevant differences between these anatomic areas when it comes to
surveillance, including the relative inaccessibility of the thoracic aorta to ultrasound interrogation and the increased
variability of thoracic aortic pathologies and post-TEVAR complications. In addition, concerns regarding radiation-
induced carcinogenesis and contrast-induced nephropathy reduce the enthusiasm of many surgeons for regular computed
tomography surveillance. Most agree that surveillance is important after TEVAR, but the method, duration, and
frequency of that surveillance is much less clear and is the topic of this debate. ( J Vasc Surg 2012;56:1786-94.)
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AORTIC REPAIR PATIENTS REQUIRE
LIFELONG FOLLOW-UP BY ANNUAL
COMPUTED TOMOGRAPHY ANGIOGRAPHY/
MAGNETIC RESONANCE ANGIOGRAPHY
Shen Wong, MD, and Tara M. Mastracci, MS, MD,
Cleveland, Ohio
Introduction. Since the first thoracic endograft was
placed in 1994 for descending thoracic aneurysm disease,1
multicenter trials2-4 and comparative analyses5 have con-
firmed reduced early morbidity and mortality over its open
counterpart.6 As such, thoracic endovascular aortic repair
(TEVAR) is now an accepted treatment for descending
TAA in the elderly and high-risk populations.7,8 These
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1786echniques have been successfully adapted for the treat-
ent of other thoracic aortic conditions such as dissec-
ion9,10 and blunt injury,11,12 bringing a younger cohort of
atients and with it, concerns regarding its long-term du-
ability and efficacy. If we can extrapolate from the infrare-
al endovascular aneurysm repair (EVAR) experience, early
eductions in morbidity and mortality may be coupled with
n increased need for reinterventions and an uncertainty in
ong-term prevention of aortic-related death.13 Similarly,
here is no evidence that TEVAR in descending thoracic
neurysmal disease is superior to its open counterpart for
ong-term outcomes.6 This paucity of convincing long-
erm data and the high need for reintervention have led to
ecommendations for lifelong surveillance.7,8
Risks of surveillance. Endograft surveillance in the
rauma population presents a very different set of consider-
tions, and the type and interval for this younger group of
atients is highly controversial and will not be included here.
owever, the consequences of lifelong surveillance deserve
onsideration in the cohorts with aneurysm and dissection
iven that TEVAR is no longer restricted to the high-risk
urgical patient.With this younger andhealthier cohort comes
oncern that the accumulated radiation dose of treatment,
ollowedby yearly lifelongCT scans, places these patients at an
ncreased risk of radiation-induced cancer.14
In some patients, there are also long-term risks to renal
unction. Forty percent of patients with descending tho-
acic aneurysms treated by TEVAR have pre-existing renal
nsufficiency (glomerular filtration rate [GFR] 60 mL/
in), and the procedure precipitates a progressive deterio-
ation in chronic renal dysfunction in almost 14%.15 This
ecline may further be exacerbated by surveillance, where
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Volume 56, Number 6 Wong et al 1787patients with a GFR 45 mL/min have a 15% risk of
contrast-induced nephropathy after a single-contrast CT
angiogram.16 Although contrast-induced nephropathy is
potentially reversible, the development of the condition
itself is associated with a twofold increased rate of stroke,
myocardial infarction, dialysis-dependent renal failure, and
death.17 The mean cost of surveillance is $1800 higher in
TEVAR-treated patients than in patients treated by open
repair at 2 years of follow-up.18
Rationale for surveillance. To justify the costs and
risks associated with TEVAR surveillance, it will be neces-
sary to show that their benefits outweigh these risks over
time. These benefits may include prevention or treatment
of graft-related issues, such as endoleak, collapse, and mi-
gration, as well as aortic issues such as remodeling and
aneurysmal degeneration of contiguous segments. The ra-
tionale would be that intervention for these issues may
Table. Multicenter trials and single-center series reporting
First author Year Patients Pathology
Mean F/U, months
Mean  SD (range)
Czerny22 2010 113 Aneurysm 54  38 (5-144)
Piffaretti21 2009 61 Aneurysm 32.4 (1-96)
Preventza20 2008 249 Mixedg 20  19.4 (1-60)
Makaroun2 2008 140 Aneurysm 37 (3-66)
Fairman4 2008 195 Mixedh 12
Matsumura3 2008 160 Mixedh 12
Morales23 2008 160 Mixedi 36 (0-78)
Leurs25 2007 213 Aneurysm 18  16.1 (1-60)
F/U, Follow-up; NR, not reported.
aW. L. Gore and Associates, Flagstaff, Ariz.
bMedtronic Vascular, Santa Rosa, Calif.
cBolton Medical, Sunrise, Fla.
dEndomed, Phoenix, Ariz.
eJotec, Hechingen, Germany.
fCook Inc, Bloomington, Ind.
gAneurysms (45%), dissections (27%), penetrating aortic ulcers (11%), conta
chial fistulas (3%), endoleaks (1%), coarctation (1%).
hAneurysms, penetrating aortic ulcers.
iAneurysms (82%), chronic dissection aneurysms (16%), other (fistula, aortireduce the risk of aneurysm-related death. iRationale for surveillance: endoleak. Endoleak rep-
esents the most common complication after TEVAR, oc-
urring in up to 30% of patients19; unlike in the abdominal
orta, it appears that type I and III endoleaks predominate.
his is a consistent finding in a number of multicenter trials
nd single-center series (Table).2-4,20-23 Type I and III
ndoleaks represent treatment failure through persistent
neurysmal sac pressurization and require immediate treat-
ent to prevent rupture and possible death.24 Type II
ndoleaks, in particular those from left subclavian artery
LSCA) coverage at the proximal seal zone, require inter-
ention because these have been associated with sac en-
argement.22 Most of these endoleaks are early (30 days)
nd can be treated within the original admission; however,
p to 21% of patients experience late endoleaks, and at up
o 2 years of follow-up, 56% of these required a secondary
oleaks
Grafts used
Endoleak, %
Early Type Late Type
uder,a Talent,b TAG,a
elay,c Valiant,b
hers,d,e
12.3 I and III, 7.9 11.5 I and III
II, 4.4
nt, Excluder, TX1/
X2f
8.2 I, 6.6 6.5 I, 4.9
II, 1.6 II, 1.6
III, 0 III, 0
6.4 I, 5.1 8.8 I, 6.1
II, 1.3 II, 1.9
III, 0.8
8.1 I, 6.1 4.3 I, 2.15
II, 1 II, 2.15
III, 1 III, 0
nt 25.9 I, 4 12.2 I, 4.9
II, 15.5 II, 4.9
III, 1.7 III, 0
Unknown,
4.6
Unknown,
2.4
4.8 I, 0.8 3.9 I, 0
II, 3.2 II, 1.9
III, 0.8 III, 1
Unknown,
1
/TX2 9.4 I, 4.4 7.5 I, 1.9
II, 4.4 II, 4.4
III, 0.6 III, 1.2
nt, X2, Excluder,
dofitd
NR NR 21.1 I, 10.3
II, 3.3
III, 7.5
uptures (5%), pseudoaneurysms (4%), aortic transections (4%), aortobron-
res, 2%); mixed.end
Excl
R
ot
Tale
T
TAG
TAG
Tale
TX2
TX1
Tale
En
ined rntervention.25
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December 20121788 Wong et alAlthough most trials have relatively limited follow-up,
Czerny et al22 reported a 5.7% type I and III late endoleak
rate in 113 TEVAR-treated descending thoracic aneurysm
patients prospectively monitored for a mean of 54 months,
after an initial early endoleak rate of 12.3%. Interestingly,
they noted that no patient with a successfully treated early
endoleak showed a late endoleak with the same cause,
suggesting that late endoleak development may not be
predicted by the presence of early endoleak. In another
series, seven of 64 persistent endoleaks at up to 40 months
of follow-up were associated with rupture, and all resulted
in death.26 Other reports of aortic rupture in TEVAR-
treated patients lost to follow-up have been noted at up to
10 years postprocedure.27 Presence of late endoleak was the
only predictor of decreased survival in a single-center pro-
spective series,28 emphasizing the potential hazards of un-
detected and untreated late TEVAR complications.
Rationale for surveillance: Migration and collapse.
Further complications of TEVAR, including graft migra-
tion29 and graft collapse, are not confined to the early
postoperative period and are also associated with late aortic
morbidity and mortality.30 Device encroachment on arch
vessel ostia have been ascribed to stent graft migration at up
to 2 years after implantation,31 and graft collapse with
proximal endoleak have been observed at up to 3 years after
implantation.32 Other rare complications of TEVAR treat-
ment observed include retrograde type A dissection, seen at
up to 4 months after implantation, and aortoesophageal
fistula at up to 49 months, both requiring open conversion
for salvage.33
Rationale for surveillance: Aortic remodeling and
detection of contiguous aneurysms. Surveillance in
TEVAR-treated dissection is also required to assess aortic
remodeling, false lumen thrombosis, and progression of
aortic disease in segments of contiguous aorta. Aortic re-
modeling and false lumen thrombosis are both predictive
for survival after TEVAR-treated chronic type B dissec-
tion,34 and surveillance is essential to monitor these end
points. Failure to maintain these end points commonly
leads to reinterventions, observed in up to 60% of patients
in a systematic review of 17 studies and 500 patients.35
Midterm (mean, 31 months) complications of distal aortic
aneurysmal change and persistent false lumen blood flow
were reported in 8% of the cohort, with proximal type I
endoleaks occurring in a further 7% and delayed aortic
rupture in 3%. In addition to monitoring the TEVAR-
treated segment, surveying the evolution of the untreated
segment susceptible to progressive dilatation is essential: in
79 patients with complicated chronic distal aortic dissec-
tion treated with TEVAR, 22% subsequently underwent
secondary aortic reinterventions predominantly for en-
largement of the untreated aorta remote to the stent graft
repair.36
Progression of disease in TEVAR-treated descending
TAA is less well described than in dissections. Aneurysmal
regression in the absence of endoleak is well reported, but
there is little information on progression of disease in areas
remote from the treated segment. However, we can expect mrogression in TEVAR-treated aneurysmal disease if we
xtrapolate from a series of 30 open surgical repair descend-
ng TAA/thoracoabdominal aortic aneurysm patients
ound to have aneurysmal degeneration in contiguous seg-
ents of aorta between 4 and 16 years after their initial
urgery.37 In these 30 patients, 12 had aneurysmal degen-
ration (of 6-cm diameter) proximal to the previous
epair, whereas 14 were distal. Reported TEVAR follow-up
o date is likely too short to allow observation of this
henomenon.
Durability unknown. The literature of TEVAR in
escending aneurysmal disease22 and aortic dissection36,38
ould suggest that late complications are ubiquitous, re-
ardless of treatment indication and model of device used.
urthermore, there appears to be no obvious threshold of
ollow-up duration after which no further complications
ccur: life-threatening late complications have been re-
orted at up to 10 years after the procedure.27 Because few
arge series report follow-up5 years, evidence of durabil-
ty of the devices used is unknown apart from the knowl-
dge that complications 5 years exist and require inter-
ention to prevent death. At the current time with the
vailable evidence, it seems prudent to continue ongoing
urveillance for TEVAR as a duration after which no further
omplications occur has not been identified, but certainly
ore long-term experience is needed.
Options for surveillance modalities. Although there
s evidence to support the need for lifelong surveillance,
onsiderable debate exists on how this should be achieved,
ecause the potential benefit of lifelong surveillance of the
raft may be outweighed by the disadvantage of excessive
adiation exposure and cost. Current-generation CT scan-
ing is ideal for imaging because it provides isovoxel images
hat can be manipulated in three planes, and with contrast
nhancement in delayed phases, it can also detect low-flow
eaks. However, Zoli et al14 estimate that the projected
umulative radiation exposure with CT over 17 years of
ollow-up exceeds 350mSv, with a lifetime attributable risk
f developing leukemia and solid cancer of between 2.7%
nd 12%. Despite this, patients with predisposing factors
or graft complications may incur a risk of late endoleak,
ith its attendant morbidity and mortality,26 that exceeds
he risk of radiation-induced malignancy, justifying the
rioritization of surveillance. Such predisposing factors in-
lude bird-beaking at the proximal seal zone,39 compro-
ised proximal seal zone due to length or angulation,28
reater length of aortic coverage and number of compo-
ents used,40 larger diameter at the proximal seal zone, and
overage of the LSCA without endovascular or open liga-
ion.21 Grafts placed along the lesser curve of a large
neurysm have the potential for outward migration, with
esultant dislocation and type III endoleak.41 In patients
hose grafts have these characteristics, annual surveillance
ith the imaging modality that best demonstrates graft
ailure, regardless of accumulated radiation dose, should be
rioritized.
Consideration of age. In younger patients, who are
ost at risk of prolonged radiation exposure, more consid-
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minimize radiation load without compromising surveil-
lance. In groups such as those with connective tissue dis-
ease, aortic dissection, and younger descending TAA pa-
tients, follow-up is likely to exceed the 10-year latency
period for malignant transformation after radiation expo-
sure.42
One strategy to reduce exposure may be to combine a
chest CT angiography (CTA) with an abdominal and pe-
ripheral ultrasound scan in patients where the primary
clinical interest is the aneurysmal progression of untreated
aortoiliac and femoral regions, rather than a total body
CTA. When a nitinol-based endograft is used, magnetic
resonance angiography (MRA) should be used preferen-
tially to reduce the radiation load. Some have argued that
they preferentially use a nitinol-based stent graft over a
stainless steel counterpart in patients with a long expected
follow-up for this specific reason.14 Where cost and institu-
tional restrictions limit annual access tomagnetic resonance
imaging (MRI), alternating annual follow-up between
CTA and MRA can prolong the duration of “radiation
safe” follow-up, effectively doubling the time needed to
reach threshold radiation exposure. In some situations,
such as assessing false lumen thrombosis in aortic dissec-
tion, specialized MRI may actually be preferred over CTA
due to its increased sensitivity in detecting the presence of
low-velocity flow.43
From a renal safety perspective, although the less-
nephrotoxic gadolinium-based contrast with MRA may
be preferred over iodinated CT contrast in moderate
renal insufficiency, caution still exists in patients with a
GFR 30 mL/min, where the risks of nephrogenic
systemic fibrosis remain a concern.44 In any patient with
impaired renal function, the recommended guidelines
for renal protection should be followed.16 Thus, patients
with a projected life expectancy of 10 years or renal
failure, or both, need greater consideration in surveil-
lance modality selection to minimize and manage its
potential negative affect.
This need for individualized surveillance strategy
begs the larger question of whether endovascular options
are truly beneficial over open options overall, especially
in patients where one cannot achieve optimal graft sur-
veillance and radiation and renal safety. Although some
groups use this dilemma to guide the optimal choice of
graft, should it rather address the broader question of
what the optimal modality of treatment should be, given
the predominant benefits of endovascular treatment are
short-term, while the benefits one seeks to achieve in
these younger fitter patients include the long-term?
Conclusions. Finally, it is important to note that en-
dovascular stent grafting is by its very nature, palliative
rather than curative in intent, relying on simply relining the
pathologic aorta rather than excising and replacing it by
open surgery. The corollary to this is that lifelong surveil-
lance is essential to monitor the equally lifelong potential
for the endograft to fail. Good outcomes have been
achieved in the elderly and high-risk patients; however, theole of endografts in the younger population has yet to be
stablished, and lifelong surveillance is critical for determin-
ng their true place in the vascular surgeons’ armamentar-
um.
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ART II: ALL THORACIC ENDOVASCULAR
ORTIC REPAIR PATIENTS DO NOT REQUIRE
IFELONG FOLLOW-UP BY ANNUAL
OMPUTED TOMOGRAPHY ANGIOGRAPHY/
AGNETIC RESONANCE ANGIOGRAPHY
Athanasios Katsargyris,MD, andEric L. G. Verhoeven,
D, PhD, Nürnberg, Germany
Introduction. Thoracic endovascular aneurysm repair
TEVAR) is associated with reduced perioperative mortal-
ty and morbidity compared with conventional surgery but
lso with a number of postoperative early and late compli-
ations that may require surgical or endovascular reinter-
ention.1-4 For that reason, TEVAR patients need to be
onitored with imaging studies. Most centers performing
EVAR have adopted strict follow-up imaging protocols.
he latter consist most commonly of repeated computed
omography angiography (CTA) or magnetic resonance
ngiography (MRA) assessments at 1, 6, and 12 months
ostoperatively and yearly thereafter.4,5 Although it is clear
hat a number of TEVAR patients will benefit from such
rotocol-led surveillance regimens, it is uncertain whether
ll TEVAR patients need annual and lifelong imaging
ollow-up. Such a protocol-led surveillance regimenmay be
nnecessary for many patients. In addition, the health risks
nd financial costs of CTA/MRA must be taken into ac-
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need annual lifelong CTA/MRA follow-up.
Need for follow-up with regard to pathology
treated by TEVAR. TEVAR was initially introduced as a
minimally invasive treatment option for thoracic aortic
aneurysms. Since then, several additional pathologies of the
thoracic aorta have been treated by TEVAR. Although
most of these pathologies are outside the manufacturers’
instructions for use, TEVAR has been applied with success
in traumatic transection, pseudoaneurysm, dissection, per-
forating ulcer, coarctation, and intramural hematoma.6-10
Reintervention rates in these pathologies compared with
TEVAR for aneurysmal thoracic disease were reported to
be lower.7 Importantly, many of these pathologies do not
represent an evolving disease process, as in the case of
degenerative thoracic aortic aneurysms, but a stable condi-
tion or post-traumatic injury requiring treatment. After a
technically successful intervention with good short-term
and midterm documented outcome, further annual CTA/
MRA may not be mandatory:
● A 23-year-old man treated successfully with a modern,
flexible thoracic stent graft (eg, Zenith Tx2 Proform,
Cook Inc, Bloomington, IN) for traumatic aortic tran-
section with a 1-year unremarkable follow-up result on
CTA could bemonitored by chest x-ray imaging yearly
or a CTA every 2 to 3 years (Fig 1).
● Similarly, a 76-year-old man treated for intramural
hematoma with a cTAG graft (W. L. Gore and Asso-
ciates, Flagstaff, Ariz) does not need a strict surveil-
lance if the 3-year follow-up CTA demonstrates an
Fig 1. Computed tomography angiography (CTA) reconstruc-
tion at 1 year after thoracic endovascular aortic repair with a Zenith
TX2 Proform for an acute aortic transaction in a 23-year-old man.unremarkable and stable situation (Fig 2). y● A 37-year-old man treated by TEVAR for a pseudoan-
eurysm in the descending thoracic aorta after several
open procedures, including an extra-anatomic bypass
from ascending-to-descending aorta, does not need a
yearly control CTA/MRA when the 8-year follow-up
result shows exactly the same outcome as the control
angiography after the initial procedure (Fig 3, A and B).
Withmanymore examples like these at hand, it seems very
easonable to individualize follow-up according to the pri-
ary TEVAR indication and to the result after treatment.
Aim of follow-up after TEVAR. Imaging follow-up
fter TEVAR aims to diagnose potential adverse events and
omplications, such as device migration, disconnection, or
ndoleak, which may require further treatment. The latter
s important and has to be taken into account to justify
xtensive follow-up imaging studies, including CTA or
RA. In modern medicine, more and more protocols are
ntroduced that do serve safety and quality purposes for the
atient and for the doctor (eg, protocols in polytrauma-
ized patients or in anesthesiology) but undoubtedly lead
o overconsumption. The clinical touch seems lost in many
reas in favor of protocol-drivenmedicine: polytraumatized
atients are subjected to extensive imaging too quickly with
learly less focus on anamnesis, clinical examination, and
linical differential diagnosis. Anesthesiology by the proto-
ol is requesting extensive preoperative investigations that
ill most likely not benefit the patient but protect the
octor from later liability issues. The increased financial
osts of such overrated protocols must be taken into ac-
ount, as well as the potential harm of some additional
nvestigations.11
There is no clear evidence to support a strict follow-up
rotocol after TEVAR. The recommendation to do so was
erived empirically from early multicenter studies using
rst-generation devices, with a clear lack of long-term data.
rotocols were introduced to evaluate a new technique.
his is no longer the case, with TEVAR being in its second
ecade. Devices and techniques have evolved and indica-
ions broadened, as mentioned above. This calls for a
pecific and individually tailored follow-up approach. Nev-
rtheless, longer-term quality data on each indication are
equired, but this should be achieved within strict study
rotocols. Potential preoperative risk (pathology treated,
natomic features) factors should be identified to define
hich patients should have a stricter follow-up regimen.
Health and financial costs of a CTA/MRA follow-up
rotocol. Several studies have demonstrated a decline in
enal function in EVAR patients related to the cumulative
ontrast load from repeated CTAs.12,13 MRA was initially
hought not to be nephrotoxic, but many studies have
hown that MRA with a single or double dose of gadolin-
um contrast agents carries a nephrotoxic effect.14-16
The potential carcinogenic effects of the cumulative
adiation exposure from CTA are also becoming more
vident.17 A TEVAR procedure, including one preopera-
ive CTA, three follow-up CTAs for the first year, and a
early evaluation thereafter results in a high radiation expo-
76-year-old patient (A) after being treated with a cTAG thoracic stent graft (B) and at the 3-year follow-up.
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endovascular aneurysm repair for pseudoaneurysm in a 37-year-old patient. This patient had been treated by openFig 2. Computed tomography angiography (CTA) shows the preoperative sagittal view of a perforating ulcer in ameans for coarctation, including an extra-anastomotic bypass from ascending-to-descending aorta.
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induced leukemia and solid-tumor cancer within 15
years.18 Younger patients, smokers, and women are carry-
ing an even higher risk.16 Three alternatives have been
advocated to reduce radiation exposure: (1) reduction of
the effective dose associated with each CTA, (2) reduction
in the number of CTAs requested, or (3) replacement of
CTA with alternative modes of imaging and assessment.19
Finally, the cost aspect must not be underestimated.
Several studies of EVAR have demonstrated that a less
intensive surveillance protocol with selective use of CTA,
duplex ultrasound imaging, and abdominal x-ray imaging
instead of standard annual follow-up with CTA is cheaper
and could make EVAR cost-effective compared with open
repair.20-23 Duplex ultrasound imaging is not applicable in
TEVAR, but x-ray imaging can still provide valuable infor-
mation on migration and disconnection. Applying a selec-
tive CTA follow-up scheme would make TEVAR more
attractive in terms of cost-effectiveness, given that imaging
costs constitute 30% to 35% of the total postimplant costs
during the 5-year period after EVAR.11
Taking the above-mentioned three arguments—
nephrotoxicity, radiation, and cost—into consideration, it
seems sensible to reduce the number of CTA/MRA after
TEVAR, whenever medically justifiable. Several options are
available: use of noncontrast CT allows for measurement of
aneurysm sac diameter, plain radiography diagnoses device
integrity and migration, intravascular ultrasound imaging
can detect endoleaks, and intrasac pressure measurements
could also play a role after TEVAR.24,25 Finally, MRA
could replace CTA in stent grafts without stainless steel.26
Conclusions. Not all TEVAR patients need to be
followed by annual and lifelong CTA/MRA. The latter
should be used with caution only to detect complications
that may require additional treatment. Follow-up schemes
with regard to method and timing should be tailored and
later adapted to the different pathologies treated by
TEVAR and according to the anatomic risk factors and the
clinical outcome. Alternative follow-up methods should
also be reconsidered in view of both health dangers and
costs associated with annual CTA/MRA.
REFERENCES
1. Alsac JM, Khantalin I, Julia P, Achouh P, Farahmand P, Capdevila C, et
al. The significance of endoleaks in thoracic endovascular aneurysm
repair. Ann Vasc Surg 2011;25:345-51.
2. Adams JD, TracciMC, Sabri S, Cherry KJ, Angle JF,Matsumoto AH, et
al. Real-world experience with type I endoleaks after endovascular repair
of the thoracic aorta. Am Surg 2010;76:599-605.
3. Dumfarth J, Michel M, Schmidli J, Sodeck G, Ehrlich M, GrimmM, et
al. Mechanisms of failure and outcome of secondary surgical interven-
tions after thoracic endovascular aortic repair (TEVAR). Ann Thorac
Surg 2011;91:1141-6.
4. Makaroun MS, Dilavou ED, Wheatley GH, Cambria RP, Gore TAG
Investigators. Gore TAG investigators. Five-year results of endovascular
treatment with the gore TAG device compared with open repair of
thoracic aortic aneurysms. J Vasc Surg 2008;47:912-8.
5. GrabenwögerM, Alfonso F, Bachet J, Bonser R, CzernyM, Eggebrecht
H, et al. Thoracic endovascular aortic repair (TEVAR) for the treatment
of aortic diseases: a position statement from the European Association
for Cardio-Thoracic Surgery (EACTS) and the European Society ofCardiology (ESC), in collaboration with the European association of
percutaneous cardiovascular interventions (EAPCI). Eur Heart J
2012;33:1558-63.
6. Song TK, Donayre CE,Walot I, Kopchok GE, Litwinski RA, Lippmann
M, et al. Endograft exclusion of acute and chronic descending thoracic
aortic dissections. J Vasc Surg 2006;43:247-58.
7. D’Souza S, Duncan A, Aquila F, Oderich G, Ricotta J, Kalra M, et al.
TEVAR for non-aneurysmal thoracic aortic pathology. Catheter Car-
diovasc Interv 2009;74:783-6.
8. Go MR, Barbato JE, Dillavou ED, Gupta N, Rhee RY, Makaroun MS,
et al. Thoracic endovascular aortic repair for traumatic aortic transec-
tion. J Vasc Surg 2007;46:928-33.
9. Midulla M, Deahene A, Godart F, Lions C, Decoene C, Serge W, et al.
TEVAR in patients with late complications of aortic coarctation repair.
J Endovasc Ther 2008;15:552-7.
0. Torsello GB, Torsello GF, Osada N, Teebken OE, Ratusinski CM,
Nienaber CA.Midterm results from the TRAVIATA registry: treatment
of thoracic aortic disease with the valiant stent graft. J Endovasc Ther
2010;17:137-50.
1. Noll RE Jr, Tonnessen BH, Mannava K, Money SR, Sternbergh WC.
Long-term postplacement cost after endovascular aneurysm repair. J
Vasc Surg 2007;46:9-15.
2. Alsac JM, Zarins CK, Heikkinen MA, Karwowski J, Arko FR, Des-
granges P, et al. The impact of aortic endografts on renal function. J
Vasc Surg 2005;41:926-30.
3. Waasdorp E, van Hullenaar C, van Herwaarden J, Kelder H, van de
Pavoordt E, Overtoom T, et al. Renal function after endovascular aortic
aneurysm repair: a single-center experience with transrenal versus infra-
renal fixation. J Endovasc Ther 2007;14:130-7.
4. Stratta P, Canavese C, Aime S. Gadolinium-enhanced magnetic reso-
nance imaging, renal failure and nephrogenic systemic fibrosis/neph-
rogenic fibrosing dermopathy. Curr Med Chem 2008;15:1229-35.
5. Ergün I, Keven K, Uruç I, Ekmekçi Y, Canbakan B, Erden I, et al. The
safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol
Dial Transplant 2006;21:697-700.
6. Shenoy C. Gadolinium-induced nephrogenic systemic fibrosis in pa-
tients with kidney and liver disease. Am J Med 2008;121:e11-13.
7. Brenner DJ, Hall EJ. Computed tomography—an increasing source of
radiation exposure. N Engl J Med 2007;357:2277-84.
8. Zoli S, Trabattoni P, Dainese L, Annoni A, Saccu C, Fumagalli M, et al.
Cumulative radiation exposure during thoracic endovascular aneurysm
repair and subsequent follow-up. Eur J Cardiothorac Surg 2012;42:
254-60.
9. White HA, Macdonald S. Estimating risk associated with radiation
exposure during follow-up after endovascular aortic repair (EVAR).
J Cardiovasc Surg (Torino) 2010;51:95-104.
0. Chambers D, Epstein D, Walker S, Fayter D, Paton F, Wright K, et al.
Endovascular stents for abdominal aortic aneurysms: a systematic review
and economic model. Health Technol Assess 2009;13:215-318.
1. Brown LC, Powell JT, Thompson SG, Epstein DM, Sculpher MJ,
Greenhalgh RM. The UK endovascular aneurysm repair (EVAR) trials:
randomised trials of EVAR versus standard therapy. Health Technol
Assess 2012;16:1-218.
2. Hayter CL, Bradshaw SR, Allen RJ, Guduguntia M, Hardman DT.
Follow-up costs increase the cost disparity between endovascular and
open abdominal aortic aneurysm repair. J Vasc Surg 2005;42:912-8.
3. Chaer RA, Gushchin A, Rhee R, Marone L, Cho JS, Leers S, et al.
Duplex ultrasound as the sole long-term surveillance method post-
endovascular aneurysm repair: a safe alternative for stable aneurysms. J
Vasc Surg 2009;49:845-50.
4. Parsa CJ, Daneshmand MA, Lima B, Balsara K, McCann RL, Hughes
GC. Utility of remote wireless pressure sensing for endovascular leak
detection after endovascular thoracic aneurysm repair. Ann Thorac Surg
2010;89:446-52.
5. Pisimisis GT, Khoynezhad A, Bashir K, Kruse MJ, Donayre CE, White
RA. Incidence and risk factors of renal dysfunction after thoracic endo-
vascular aortic repair. J Thorac Cardiovasc Surg 2010;140:S161-7.
6. Eggebrecht H, Zenge M, Ladd ME, Erbel R, Quick HH. In vitro
evaluation of current thoracic aortic stent-grafts for real-time MR-
guided placement. J Endovasc Ther 2006;13:62-71.
